SCHEMBL193074

SCHEMBL193074

Cc1cc(Cl)ccc1CN

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.46
CYP2A6 P11509 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
MAPK1 P28482 1/20 0.43
CYP2C19 P33261 1/20 0.43
IDO1 P14902 3/20 0.41
PNMT P11086 3/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
GAA P10253 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LOXL2 Q9Y4K0 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9479134 0.84 CYP3A4 (0.45) CYP3A4CYP2A6IDO1PNMTHTT
SCHEMBL1570096 0.83 TAAR1 (0.52) CYP3A4IDO1ALDH1A1
SCHEMBL1640771 0.82 CYP3A4 (0.52) CYP3A4CYP2A6IDO1PNMTHTT
SCHEMBL15093979 0.81 CYP3A4 (0.48) CYP3A4CYP1A2CYP2C9MAPK1CYP2C19
Hydrochloric Acid SCHEMBL14157241 0.81 TAAR1 (0.50) CYP3A4IDO1SMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL31129160 0.80 CYP3A4 (0.50) CYP3A4CYP2A6IDO1PNMTHTT
SCHEMBL27628619 0.79 CYP3A4 (0.43) CYP3A4CYP2A6CYP1A2CYP2C9MAPK1
SCHEMBL998743 0.79 CYP3A4 (0.43) CYP3A4CYP2A6CYP1A2CYP2C9MAPK1
SCHEMBL171203 0.79 CYP3A4 (0.43) CYP3A4CYP1A2CYP2C9MAPK1CYP2C19
SCHEMBL701343 0.78 CYP2A6 (0.48) CYP3A4CYP2A6CYP1A2CYP2C9MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117105800-B Pendimethalin hapten, pendimethalin antigen, pendimethalin antibody and preparation method and application of pendimethalin hapten, pendimethalin antigen and pendimethalin antibody 贵州国芯生物科技有限公司 2025-06-24 CN claimed
CN-117105800-A Pendimethalin hapten, pendimethalin antigen, pendimethalin antibody and preparation method and application of pendimethalin hapten, pendimethalin antigen and pendimethalin antibody 贵州国芯生物科技有限公司 2023-11-24 CN claimed
US-20120041225-A1 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF VAIDYA NITEEN A (US) 2012-02-16 US claimed
EP-1981831-A2 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF Vaidya, Niteen A. (US) 2008-10-22 EP claimed
WO-2007092264-A2 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF VAIDYA NITEEN A (US) 2007-08-16 WO claimed
US-20070185346-A1 Kit for automated resolving agent selection and method thereof VAIDYA NITEEN A 2007-08-09 US claimed
CN-117105800-B Pendimethalin hapten, pendimethalin antigen, pendimethalin antibody and preparation method and application of pendimethalin hapten, pendimethalin antigen and pendimethalin antibody 贵州国芯生物科技有限公司 2025-06-24 CN disclosed
US-20250136594-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-01 US disclosed
EP-4469438-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 EP disclosed
CN-115093389-B 6-Amide chroman-3-carboxamide derivative, preparation method and application thereof 广州医科大学 2024-10-18 CN disclosed
WO-2024199457-A1 COMPOUND HAVING RING FUSED STRUCTURE, PREPARATION METHOD THEREFOR AND USE THEREOF, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 苏州安赛隆医药科技有限公司 2024-10-03 WO disclosed
CN-118724903-A Compound with fused ring structure, its preparation method and use, and pharmaceutical composition and use 苏州安赛隆医药科技有限公司 2024-10-01 CN disclosed
CN-117105800-A Pendimethalin hapten, pendimethalin antigen, pendimethalin antibody and preparation method and application of pendimethalin hapten, pendimethalin antigen and pendimethalin antibody 贵州国芯生物科技有限公司 2023-11-24 CN disclosed
EP-1097128-B1 IMIDAMIDE DERIVATIVES BAYER CROPSCIENCE AG (DE) 2004-05-12 EP disclosed
WO-2004024728-A2 PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-03-25 WO disclosed
US-6638979-B1 Imidamide derivatives BAYER AKTIENGESELLSCHAFT (DE) 2003-10-28 US disclosed
CN-1314881-A Imidamide derivatives BAYER AG (DE) 2001-09-26 CN disclosed
EP-1097128-A1 IMIDAMIDE DERIVATIVES Bayer Aktiengesellschaft (DE) 2001-05-09 EP disclosed
WO-2000003976-A1 IMIDAMIDE DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2000-01-27 WO disclosed
US-4052191-A HERBICIDE VELSICOL CHEMICAL CORPORATION (US) 1977-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136594-A1 COMPOUNDS AND METHODS OF USE CNKSR1, UGT1A1, REV1 CYP3A4 100/4885CYP2A6 30/4885CYP1A2 6/4885
US-20120041225-A1 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF ACKR3, KIT, C3AR1 CYP3A4 292/4885CYP2A6 381/4885CYP1A2 1252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.